Full List Of Stories
Tuesday preview: US elections, Associated British Foods in focus
All eyes on Tuesday will be on the US elections, even if the results won't start to be known - under a best case scenario - until the next day.
Europe close: Stocks reverse early losses, strategists constructive
European shares bounced back at the start of the week as better-than-expected reading on factory sector activity out of China, India and the US helped to steady investor sentiment.
Sector movers: Big Oil, Aerospace and Defence bounce back
Some of the more beaten down areas of the London stockmarket paced gains at the start of the week, amid bottom-picking by some investors even in the face of the uncertainty posed by the 3 November elections the next day.
US factory PMI jumps past forecasts in October, ISM says
Factory sector activity in the US accelerated substantially last month, amid a surge in new orders, the results of a closely-followed survey showed.
JP Morgan sees 50% upside for BAE Systems, stays at 'overweight' on Ultra Electronics
Analysts at JP Morgan reiterated their 'overweight' stance for shares of BAE Systems and Ultra Electronics, among other European defence stocks, arguing that investors' concerns were overdone - and already more than priced into those companies' shares.
Russia to discuss three-month delay to tapering oil output curbs
Crude oil futures rallied from their intraday lows after reports that Russia was considering postponing plans to taper the oil output curbs now in place by three months.
Bytes Technology mulling whether to go ahead with London IPO
Bytes Technology Group is considering whether to go ahead with an initial public offering on the London Stock Exchange.
Curevac Covid-19 vaccine generates immune response in early trial
German biotechnology outfit CureVac NV's experimental Covid-19 vaccine generated an immune response comparable to that of recovered patients.
AstraZeneca Covid-19 vaccine to be widely distributed by end Q1 2021 - report
The Covid-19 vaccine being developed by AstraZeneca and Oxford University could be in advanced stage of distribution by the end of the first quarter of 2021.